These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35668042)

  • 1. Dupilumab in children with moderate-to-severe asthma: A cost utility analysis.
    Buendía JA; Patiño DG
    Pediatr Pulmonol; 2022 Oct; 57(10):2313-2319. PubMed ID: 35668042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
    Antonio Buendía J; Patiño DG
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):575-580. PubMed ID: 34860616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
    Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
    Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia.
    Jefferson Antonio B; Patiño DG; Lopez Moreno M
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):299-305. PubMed ID: 34143703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
    Andersson M; Janson C; Kristensen T; Szende A; Golam S
    J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore.
    Tan LE; Tan WHG; Aziz MIA; Koh MS; Tay TR; Pearce F; Ng K
    J Asthma; 2022 Jan; 59(1):189-199. PubMed ID: 33058740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost utility of vitamin D supplementation in adults with mild to moderate asthma.
    Antonio Buendía J; Rodriguez-Martinez CE; Sossa-Briceño MP
    J Asthma; 2023 May; 60(5):951-959. PubMed ID: 35920247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pediatr Pulmonol; 2021 Sep; 56(9):2987-2996. PubMed ID: 34143576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma.
    Buendía JA; Patiño DG
    BMC Pulm Med; 2021 Dec; 21(1):397. PubMed ID: 34865628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
    Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
    J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
    Lam J; Hay JW; Salcedo J; Kenyon NJ
    J Asthma; 2019 Aug; 56(8):872-881. PubMed ID: 30003833
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in Spain.
    González-Barcala FJ; Muñoz-Gall X; Mariscal E; García A; Yang S; van de Wetering G; Izquierdo-Alonso JL
    J Med Econ; 2021; 24(1):874-882. PubMed ID: 34114935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
    Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
    Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
    Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
    BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
    Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.